Cancer Research UK adds Astex molecule to development programme
This article was originally published in Scrip
Cancer Research Technology(CRT), Cancer Research UK's development and commercialisation arm, has signed a deal with Astex Therapeuticsto take into development its novel anticancer treatment AT13148, a small-molecule inhibitor of protein kinase B (also known as AKT). AKT is involved in the growth and survival of tumour cells in many different cancers, and the PI3-AKT pathway is being targeted by many drugs, including the mTOR inhibitors on the market or in development and the PI3K inhibitors in development. AT13148 will enter CRT's clinical development partnerships programme, which was set up in 2006 and began developing AstraZeneca's AZD0424 in May (Scrip Online, May 19th, 2008). Development of the molecule will be funded primarily by Cancer Research UK and the charity will receive a share of any revenues including a royalty on sales.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.